Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rosuvastatin,Clopidogrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
USV Launches Roseday CV at a Patient-Centric Price for Indian Cardiac Patients
Details : Roseday CV (rosuvastatin + clopidogrel) is a fixed dose combination which is approved for the treatment of cardiac diseases like heart attack, angina & stroke.
Brand Name : Roseday CV
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2023
Lead Product(s) : Rosuvastatin,Clopidogrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rosuvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rosuzet is a combination of rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts the precursor of cholesterol and ezetimibe, a sterol transporter, NPC1L1, which is involved in the intestinal uptake of cholesterol.
Brand Name : Rosuzet
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2023
Lead Product(s) : Rosuvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : JB Pharma
Deal Size : $37.9 million
Deal Type : Divestment
JB Pharma To Acquire The Entire Razel (rousvastatin) Franchise From Glenmark Pharmaceuticals Ltd
Details : Razel (rosuvastatin) is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.
Brand Name : Razel
Molecule Type : Small molecule
Upfront Cash : $37.9 million
December 14, 2022
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : JB Pharma
Deal Size : $37.9 million
Deal Type : Divestment
Lead Product(s) : EDP-235,Midazolam,Rosuvastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : EDP-235 achieved excellent penetration into monocytes and macrophages, including lung AM. EDP-235 has the potential to eliminate viral replication of SARS-CoV-2 in these critical immune cells, thus mitigating macrophage-mediated cytokine storm in high-ri...
Brand Name : EDP-235
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : EDP-235,Midazolam,Rosuvastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Apabetalone,Atorvastatin,Rosuvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease p...
Brand Name : RVX000222
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2022
Lead Product(s) : Apabetalone,Atorvastatin,Rosuvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Colchicine,Rosuvastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yale-led Clinical Trial Offers Hope for COVID Patients and a Path Forward for Research
Details : COLSTAT clinical trial (Colchicine/Statin for the Prevention of COVID-19 Complications) will combine two broadly available medications, colchicine and rosuvastatin, to help reduce complications in Covid-19 infected patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Colchicine,Rosuvastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Grunenthal
Deal Size : $350.0 million
Deal Type : Agreement
Grünenthal Closes Deal with AstraZeneca for European Rights to CRESTOR™ (Rosuvastatin)
Details : Under the terms of this agreement, Grünenthal has acquired the exclusive rights to market CRESTOR™ and its second brands in more than 30 European markets.
Brand Name : Crestor
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Grunenthal
Deal Size : $350.0 million
Deal Type : Agreement
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Grunenthal
Deal Size : $350.0 million
Deal Type : Divestment
AstraZeneca's Crestor to be Divested to Grünenthal in Europe
Details : Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. The deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain.
Brand Name : Crestor
Molecule Type : Small molecule
Upfront Cash : $320.0 million
December 01, 2020
Lead Product(s) : Rosuvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Grunenthal
Deal Size : $350.0 million
Deal Type : Divestment
LOOKING FOR A SUPPLIER?